FGFR2 and neoplasm: E7090 has been shown in NCT04238715 Phase II to have strong anti-tumor efficacy (ORR of 30%; DCR of 79%) and to be safe and controlled in the treatment of CCA patients with FGFR2 gene fusion [151].